Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
At the center of the lawsuit is Teva Pharmaceutical, slated to sell a generic version of the HIV prevention pill PrEP next year.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
The FDA approves three new, cheaper combination ARV tablets.
A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.
The tablet contains the same combo as Symfi Lo (efavirenz/lamivudine/tenofovir disoproxil fumarate) but with a higher dose of efavirenz.
Symfi Lo contains efavirenz, lamivudine and tenofovir disoproxil fumarate (TDF); Cimduo contains TDF and lamivudine.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.